NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.65 -0.06 (-3.51 %)
(As of 11/19/2018 04:00 PM ET)
Previous Close$1.71
Today's Range$1.65 - $1.73
52-Week Range$1.48 - $4.09
Volume156,757 shs
Average Volume550,563 shs
Market Capitalization$127.17 million
P/E Ratio-1.96
Dividend YieldN/A
Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI


Debt-to-Equity Ratio0.05
Current Ratio14.68
Quick Ratio14.68


Trailing P/E Ratio-1.96
Forward P/E Ratio-2.20
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.81 per share
Price / Book0.91


EPS (Most Recent Fiscal Year)($0.84)
Net Income$-42,010,000.00
Net MarginsN/A
Return on Equity-43.82%
Return on Assets-40.76%


Outstanding Shares74,370,000
Market Cap$127.17 million

Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How were Sierra Oncology's earnings last quarter?

Sierra Oncology Inc (NASDAQ:SRRA) released its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03. View Sierra Oncology's Earnings History.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Sierra Oncology.

Has Sierra Oncology been receiving favorable news coverage?

Media stories about SRRA stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sierra Oncology earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of Sierra Oncology's key competitors?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:
  • Dr. Nicholas R. Glover, Pres, CEO & Director (Age 49)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 61)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 63)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 44)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 49)

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (4.30%), Prosight Management LP (3.66%), Renaissance Technologies LLC (3.03%), Citadel Advisors LLC (2.46%), Sphera Funds Management LTD. (1.38%) and Algert Global LLC (0.53%). Company insiders that own Sierra Oncology stock include Angie You and James N Topper. View Institutional Ownership Trends for Sierra Oncology.

Which major investors are selling Sierra Oncology stock?

SRRA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Sphera Funds Management LTD.. View Insider Buying and Selling for Sierra Oncology.

Which major investors are buying Sierra Oncology stock?

SRRA stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Citadel Advisors LLC, Renaissance Technologies LLC, Algert Global LLC, Acadian Asset Management LLC and Bridgeway Capital Management Inc.. Company insiders that have bought Sierra Oncology stock in the last two years include Angie You and James N Topper. View Insider Buying and Selling for Sierra Oncology.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $1.65.

How big of a company is Sierra Oncology?

Sierra Oncology has a market capitalization of $127.17 million. The biotechnology company earns $-42,010,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Sierra Oncology employs 57 workers across the globe.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]

MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel